AOD 9604 2mg is a synthetic peptide derived from the C-terminal fragment (amino acids 177-191) of human growth hormone (hGH), modified with a tyrosine residue for stability. Each vial contains 2mg of lyophilized AOD 9604, requiring reconstitution with bacteriostatic water for use in research settings. It is designed to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat formation), primarily through activation of beta-3 adrenergic receptors in adipose tissue, as shown in studies on obese mice. Unlike hGH, it does not affect insulin sensitivity or blood glucose levels, making it a safer candidate for obesity research.
In research, AOD 9604 2mg is studied for its potential to reduce body fat, particularly in the abdominal region, and improve metabolic profiles without the side effects of full hGH, such as hyperglycemia or cell proliferation. Preliminary studies also suggest benefits in cartilage and joint repair, potentially aiding conditions like osteoarthritis. Its non-hormonal classification and lack of impact on IGF-1 levels enhance its safety profile for long-term studies. However, AOD 9604 is not FDA-approved for human use and is banned by WADA due to its performance-enhancing effects.
AOD 9604 2mg is administered via subcutaneous injection after reconstitution. Researchers must handle it with sterile techniques and consult institutional guidelines, as it is intended solely for laboratory use. Proper reconstitution and storage are critical to maintain peptide stability.
Benefits
-
Enhances fat burning by stimulating lipolysis in adipose tissue
-
Inhibits fat storage, reducing new fat accumulation
-
No significant impact on blood sugar or insulin levels
-
May support cartilage and joint repair, per preliminary research
-
Improves metabolic health and lipid profiles in obesity studies
-
High safety profile with minimal side effects in research settings
Side effects
Despite its benefits, AOD 9604 2mg may cause the following side effects:
-
Mild irritation or redness at the injection site
-
Headaches or fatigue in some research subjects
-
Potential for minor digestive upset, such as nausea
-
Risk of contamination if sterile techniques are not followed
-
Possible immune response in rare cases
-
Banned by WADA, posing risks for athletes in drug testing
These can be managed by using sterile equipment, rotating injection sites, or consulting research protocols. Non-FDA-approved status requires strict adherence to research guidelines.
Dosages & Protocol – administered via subcutaneous injection
Dosages:
-
Beginner: 300mcg per day
-
Intermediate: 300–400mcg per day
-
Advanced: 400–500mcg per day, under strict research oversight
Reconstitute with 2ml bacteriostatic water to yield 1000mcg/ml (1mg/ml). For a 300mcg dose, draw 0.3ml (30 units on a 1ml insulin syringe). Administer daily, ideally in the morning, rotating sites (e.g., abdomen, thigh). Conduct 8–12 week cycles, with vial usage of ~9 vials for 300mcg/day or ~14 vials for 500mcg/day over 8 weeks. Use within 30 days post-reconstitution and store at 2–8°C.
How to administer – reconstitution and how to inject
AOD 9604 2mg is provided as a lyophilized powder requiring reconstitution with bacteriostatic water.
Reconstitution:
-
Remove plastic caps from the vial and bacteriostatic water ampule
-
Disinfect rubber stoppers with an alcohol swab
-
Draw 2ml bacteriostatic water into a sterile syringe
-
Inject water slowly along the vial wall to minimize foaming
-
Gently swirl (do not shake) until fully dissolved
-
Store reconstituted solution at 2–8°C, use within 30 days
Injection:
-
Use a 1ml insulin syringe with a 30-gauge needle
-
Draw 0.3–0.5ml (30–50 units) for 300–500mcg doses
-
Clean the injection site (e.g., abdomen, thigh) with an alcohol swab
-
Inject subcutaneously at a 45–90° angle, pinching the skin
-
Inject slowly and rotate sites to avoid irritation
-
Use a new sterile syringe for each injection
Storage
-
Store lyophilized vial at -20°C for long-term or 4°C for short-term use
-
Store reconstituted solution at 2–8°C, away from light and heat
-
Avoid freeze-thaw cycles; use within 30 days of reconstitution
-
Keep vial and ampule sealed tightly when not in use
Half life & detectability
Half-Life: Approximately 2–3 hours, with lipolytic effects persisting longer due to receptor activation. Detection Time: Detectable in urine for up to 1–2 weeks, depending on dosage, metabolism, and testing sensitivity. AOD 9604 is banned by WADA as a performance-enhancing peptide.
For athletes subject to drug testing, it is important to consider these detection times and plan accordingly to avoid positive tests for banned substances.
